NextBio Life Science Search Engine Advances Systems Biology Approach to Research : Human Disease-Associated Mutation and Mouse Knockout Data Now Part of Rich Collection of Gene Expression Studies Available for Search

Share Article

NextBio’s life science search engine significantly advances the systems biology approach to R&D and drug discovery, says NextBio co-founder Ilya Kupershmidt, who will discuss the innovative research tool at the Beyond Genome Conference this week. He will also update the life science community on the latest additions to NextBio’s content base, including new human disease mutation and mouse knockout data sets. NextBio is the leading life sciences search engine and enterprise Software-as-a-Service (SaaS) solution being used by thousands of researchers every day and the world’s leading pharmaceutical and biotech companies. The Beyond Genome conference is being held in San Francisco from June 8 – 11.

News Image
by letting scientists around the globe easily share information and collaborate as never before.

"We recently reached another milestone in the development of the NextBio life science search engine by integrating human disease-associated mutation and mouse knockout data with the rich collection of gene expression studies already available to users," stated Mr. Kupershmidt, Vice President of Product Management at NextBio. "The new types of measurements add another dimension to NextBio's life science search engine by providing common human gene mutations and mouse gene knockouts associated with cancer, and neurological and metabolic disorders, amongst others."

On Tuesday, June 10 at 3:35 pm, Mr. Kupershmidt will present the latest innovations of the NextBio life science search engine, including several different search strategies of use to both commercial and academic researchers and new content. Among the new features to be presented: easily searchable clinical trial information, expanded experimental data sets, enhanced literature search, advanced query capabilities, added enterprise security and new APIs.

NextBio recently announced the public launch of the free version of its life science search engine, enabling any researcher or clinician to search the world's public life sciences data and literature. Moreover, by becoming a registered user of NextBio, researchers can import their own experimental data into the NextBio search engine, share it with the community and collaborate with others. "Our goal at NextBio is to support and advance the vision of Open Biology," said Mr. Kupershmidt, "by letting scientists around the globe easily share information and collaborate as never before."

NextBio is a sponsor and presenter at the Beyond Genome conference, and representatives from the company will be available from June 8-11 to discuss the NextBio life science search engine and its applications as an essential tool for every life sciences researcher and clinician. NextBio will also be hosting an on-line presentation of NextBio and its capabilities on Friday, June 13, at 11 am PDT. This presentation will cover applications of NextBio across diverse research settings both within academic and commercial organizations.

More information on the "Beyond Genome" conference and NextBio Webinar can be found at http://www.nextbio.com/b/corp/events.nb.

About NextBio

NextBio is a privately held, venture-backed company that provides an innovative search engine specifically for the life science community. NextBio provides instant access and search, user-generated content and collaboration to scientists and clinicians worldwide, enabling them to access and understand the world's life sciences information to find important new correlations, make discoveries, and generate hypotheses as never before. NextBio is implemented via a Software-as-a-Service (SaaS) model that enables users to search directly or via internal company sites through the NextBio Application Programming Interface (API). The enterprise version of the NextBio search engine is being used in life science R&D and drug development by researchers and clinicians at Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Celgene, Genzyme, Eli Lilly and Company, and Regeneron Pharmaceuticals, among others. For more information on the company, please visit our website at http://www.nextbio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joan Kureczka
NextBio
415-821-2413
Email >
Visit website